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ABSTRACT 
BACKGROUND:  The etiology of benign prostatic hyperplasia (BPH) is not completely 
understood, but hormonal changes in aging men seem to be pivotal. Dihydrotestosterone, 
a potent, active metabolite of testosterone, is formed by the enzymatic action of prostate 
5o~-reductase and causes cell growth and hyperplasia. Consistent with this action, male 
sexual dysfunction has been clinically documented to be among the drug-related 
adverse vents associated with 5o~-reductase inhibitors. The lipidosterolic extract 
of saw palmetto (LESP) fruit (Serenoa repens) has been used to treat BPH. D-004, a 
lipid extract ofRoystonea regia Royal palm fruit, has been found to prevent prostatic 
hyperplasia induced by testoste-rone in rodents and to competitively inhibit prostate 
5o~-reductase activity in vitro. 
OBJECT IVE:  The purpose of this study was to assess the effects of D-004 and 
LESK administered as single or repeated oses, on the sexual activity in male rats. 
METHODS:  This controlled, experimental study was conducted at the Pharma- 
cology Department, Centre of Natural Products, National Centre for Scientific 
Research, Havana City, Cuba. Adult male Wistar rats weighing 250 to 300 g were 
randomized into 5 groups: 2 groups treated orally with D-004 (400 and 800 mg/kg); 
2 groups treated orally with LESP (400 and 800 mg/kg); and 1 control group orally 
administered a water vehicle. Sexual activity behavior (the number of mounts and 
intromissions, mount latency, and intromission latency) was assessed uring 2 observa- 
tion periods: 90 minutes after the initial dose and at the end of the 30-day treatment. 
Latency was defined as time elapsed between the first mount and intromission. 
RESULTS:  A total of 50 rats (mean [SD] age, 10 [3] weeks; mean [SD] weight, 
295 [10] g) were included in the experiment. There were no significant difterences in the 
mean number of mounts, intromissions, mount latency, or intromission latency in the 
groups treated with single or repeated oses of D-004 or LESP (400 and 800 mg/kg) 
compared with the controls. There was also no between-group difterence in mating 
behavior among the active treatment groups. All rats survived up to study completion, 
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with normal behavior (weight gain, food intake, daily observations, without any sign of 
toxicity). There were no observable adverse vents during the study. 
CONCLUSIONS:  D-004 and LESP administered asa single dose or repeated doses for 
30 days did not significantly affect male rat sexual activity behavior compared with a vehicle 
control group. (Cuff Ther Res Cliel Exp. 2008;69:65 74) © 2008 Excerpta Medica Inc. 
KEY WORDS:  D-004, Roysto~ea fegia, saw palmetto, Sefe~oa fepe~s, rat mating 
behavior, rat sexual activity. 
INTRODUCTION 
Benign prostatic hyperplasia (BPH), a common disease in men aged >50 years 
occurring in -24% of men in their 50s, -30% of men in their 60s, and -50% of men 
aged >70 years is the increased growth of the prostate gland, which leads to lower 
urinary tract symptoms (LUTS) and complications including frequency and difficulty 
in urination. 1 6 
Although the etiology of BPH is not completely understood, hormonal changes 
in aging men seem to be a precursor to the condition. Growth and development of 
the prostate gland depend on androgen stimulation, primarily dihydrotestosterone 
(DHT),4 9 a potent, active metabolite of testosterone formed through the enzymatic 
action of prostate 5o~-reductase. With aging, DHT accumulates and binds to spe- 
cific prostate receptors, causing cell growth and hyperplasia. <9 BPH also involves the 
augmented tone of prostate smooth muscle mediated through ~l-adrenoreceptors. 1° 
Therefore, prostate 5o~-reductase inhibitors 11 13 and o~l-adrenoreceptor blockers 13 are 
first-line pharmacologic options to treat BPH. While o~l-adrenoreceptor blockers are 
effective in relaxing smooth muscle and improving LUTS, 14 prostate 5~-reductase 
inhibitors mainly reduce prostate nlargement and prevent complications (eg, irritation, 
lower urinary tract infections, hematuria, vesical incontinence) from occurring. 11,12 
Consistent with their mechanism of action, male sexual dysfunction has been clini- 
cally documented to be among the drug-related adverse vents (AEs) associated with 
5o~-reductase inhibitors, particularly finasteride. 1114 
Sefeeloa fepevs, commonly referred to as saw palmetto, is an herbal medicine used 
to treat a variety of conditions, including chronic pelvic pain, bladder and urinary 
disorders, and hormone imbalances. 15 17 The lipidosterolic extract of saw palmetto 
(LESP) berries has been used to treat BPH. 15 17 Clinical trials 13,16 19 have found LESP 
to be effective in the treatment of BPH, and the effects of LESP have been found to 
be comparable to the effects of finasteride (a specific inhibitor of type II 5o~-reductase) 
and tamsulosin (an antagonist of 5Oq-adrenoreceptors). However, 2 recent placebo- 
controlled trials 2°,21 did not find significant differences between LESP and placebo in 
the treatment of BPH. 
LESP appears to improve BPH through multiple mechanisms rather than a sin- 
gle mechanism. 16It has been found to competitively inhibit prostate 5o~-reductase 
activity.22 27 This effect is believed to be associated with oleic, lauric, and myristic free 
fatty acids and not esterified acids or other compounds present in LESE 2s Despite this 
antiandrogenic mechanism, clinical studies 13,16,2s have found that the effects of LESP 
66 
L .C .  FERN/~NDEZ ET AL .  
on male sexual function were similar to those of placebo without the AEs associated 
with finasteride. A search of the literature for English language articles using PubMed 
(inception through March 2007) database and key terms saw palmetto, Serenoa repens, 
saw palmetto lipid extract, rat copulatory behavior, and rat mating behavior, did not identify 
experimental studies on the eftects of LESP on male sexual function. 
D-004 is a lipid extract of Royal palm (Roystonea regia) fruit, which contains a repro- 
ducible mixture of free fatty acids, with oleic acid being the most abundant, followed by 
lauric, palmitic, and myristic acids. In experimental studies, 29 33 D-004 has also been 
found to competitively inhibit rat prostate 5o~-reductase activity in vitro and to prevent 
prostatic hyperplasia (PH) induced with testosterone (not with DHT) in rodents treated 
orally (200 800 ms/ks) for 14 days. This finding suggests that treatment with D-004 
might positively aftect male sexual activity. 
Most of the current knowledge of male sexual behavior and function has been derived 
from experimental studies in rats. 34 37 Successive tests that record the number of mounts 
and intromissions in the presence of estrogenized females found that rats usually display 
stable (ie, same pattern of mounts and intromissions in front of receptive females within 
the same timeframe [hour or day] and environmental conditions as per rat strain) sexual 
activity over time. 34,37 This model has been used to explore the eftects of antihypertensive 
and vasodilator drugs on male rat sexual activity. Additionally, preclinical studies 34 37 
in male rats have provided a better understanding of male sexual activity functions (eg, 
penile erection, ejaculatory ability) as well as male sexual activity in general. This particu- 
lar model has been used to assess the potential eftects of antihypertensive drugs, nitro- 
prusside, sildenafil, the extracts of Ferula hermonis root, Ruta graveolens L, and the flavonoids 
from Semen cuscutae xtract on male sexual activity in vivo. 34'37 40 
This study was undertaken to assess whether oral treatment with D-004 or LESP 
aftects exual activity in male rats. 
MATERIALS  AND METHODS 
ANIMALS 
This experimental study was conducted at the Pharmacology Department, Centre of 
Natural Products, National Centre for Scientific Research, Havana City, Cuba. Fifty- 
two adult male Wistar rats (weight, 250 300 g) were acquired from the Center for 
Laboratory Animal Production (CENPALAB, Havana, Cuba) and maintained at labo- 
ratory conditions (temperature [range], 25 [+2]°C, relative humidity 65% [+5%], and 
12-hour light and darkness cycles) with free access to food (rodent chow) and water. 
Because the eftect of treatment that impairs or enhances exual activity should be 
assessed after the rat achieves a stable copulatory pattern, 4° healthy, sexually experi- 
enced male rats that demonstrated brisk sexual activity were selected for the study. 
Before treatment commencement, male rats' sexual behavior (ie, olfactory exploration of 
female anus and genitals, attempted mounts, and penile erections) was assessed. Those 
that did not exhibit sexual interest in estrogenized females were excluded from the study. All 
52 male rats were assessed for inclusion. Of this number, 2 were excluded from the study. 
Therefore, a total of 50 rats were included in the study. Rats were housed in individual 
cages during the study. 
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This study was conducted in accordance with the Cuban regulations for the use of 
laboratory animals and ethical principles for animal management. 41 The study protocol 
was reviewed and approved by an institutional review board of the Centre of Natural 
Products (Havana City, Cuba), whose members are independent of those participating 
in this study. 
TREATMENT AND DOSAGE 
D-004 was obtained from the Chemistry Department of the Centre of Natural 
Products, where its composition and purity were assessed using a validated fisons gas 
chromatograph (8000 series, Thermo Fisher Scientific, Milan, Italy) with a flame ioniza- 
tion detector (FID) using a Solgelwax column (30 mm × 0.25 btm film thickness; 0.25 mm 
internal diameter). The free fatty acid methyl esters were prepared by methylation 
with acetyl chloride-methanol (10:90, v/v). The oven was heated from 80°C to 180°C 
at 20°C/min and from 180°C to 280°C at 4°C/min. The injector and detector were 
set at 270°C and 275°C, respectively. Hydrogen 1.3 mL/min was used as the carrier 
gas. 
Each peak observed with the FID was confirmed using standards of each acid 
(Sigma-Aldrich Corporation, St. Louis, Missouri). Concentrations were calculated from 
the peak areas using tridecanoic acid as the internal standard. 
The free fatty acid composition of D-004 was as follows: caprylic (C8: 0) 0.4%; capric 
(C10:0) 0.5%; lauric (C12:0) 27.0%; myristic (C14:0) 8.5%; palmitic (C16:0) 11.1%; palmi- 
toleic (C16:l) 0.4%; stearic (Cl8:0) 2.0%; oleic (Cl8:l) 28.5%; linoleic (C18:2) 9.5%; and 
linolenic (C18:3) 2.0%. The free fatty acid composition of the saw palmetto capsules* 
was as follows: caprylic (C8: 0) 1.4%; capric (C10:0) 0.9%; lauric (C12:0) 16.5%; myristic 
(C14:0) 6.2%; palmitic (C16:0) 9.0%; palmitoleic (C16:1) 0.1%; stearic (Cl8:0) 2.6%; oleic 
(C18:1) 29.8%; linoleic (C18:2) 21.5%; and linolenic (C18:9 2.3%. During the experiments, 
capsules were emptied immediately before their content was administered. 
Both D-004 and LESP were suspended in a 2% BDH Tween 65 (VWR International 
Ltd., Lutterworth, United Kingdom) water solution immediately before use and admin- 
istered orally by gastric gavage (5 mL/kg). In the first observation period, rats were 
assessed for 90 minutes after the administration of a single dose of the study drug. 
Following the single-dose administration, repeated oses of the drugs were adminis- 
tered daily in the morning (8:30 AM 10:00 AM) 6 days a week for 30 days; the last dose 
was administered the day before the second observation assessment. 
Male rats were equally randomized into 5 groups: 2 groups received D-004 (400 
and 800 mg/kg); 2 groups received LESP (400 and 800 mg/kg), and the control group 
received the Tween water vehicle. Previous tudies 29 33 have found these corresponding 
doses to be effective in preventing PH induced with testosterone in rats. 
All rats were observed at least once daily for 1 hour (8:30 AM 9:30 AM) tO monitor 
for overt signs of toxicity and changes in behavior. Food and water intake were moni- 
tored and recorded. 
*Trademark: Proseren ®(Blackmores Ltd., Sydney, Australia). 
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BEHAVIOR 
The female rats were ovariectomized and artificially brought into estrus with single 
IM doses of estradiol benzoate (0.5 mg/kg) and progesterone (5 mg/kg) administered 72 
and 6 hours, respectively, before each assessment. 
The receptivi U of the female rats, defined as the presence of the typical lordosis be- 
havior (including ear movement plus classical body S-shape position of female rats, 
for attracting the males) was assessed before the first observation period by expos- 
ing them to males other than the control and test animals. Only those exhibiting ood 
(ie, exhibiting lordosis behavior) sexual receptivity were used to serve as sexual 
stimulus. 
Male sexual behavior activity (mounts, mount latency lie, the time (measured by 
chronometer) elapsed from the moment of introducing the male in front of the female 
up to the first mount and intromission], intromissions, and intromission latency) was 
assessed between 6:00 PM and 7:00 PM. Male rats were placed in a transparent rectan- 
gular box (90 cm x 25 cm x 30 cm), and then were placed within a cubicle with noise- 
protected wails for an adaptation period of 5 minutes, at which time a sexually receptive 
female was then placed in the observation arena. Immediately following, the observa- 
tion began and continued for 1 hour. The number of mounts, mount latency, the num- 
ber of intromissions, and intromission latency were recorded. The assessment was ter- 
minated if the male rat failed to display sexual interest (no olfactory anal-genital exploration 
of females, attempted mounts, or penile erections) in the female rat within the first 
30 minutes of exposure. 
STAT IST ICAL  ANALYSES 
To ensure a power of 80% to detect a difference of 30% in the mounting rate 
between the treatment groups receiving D-004, LESR or the vehicle, with an O~ error 
of 0.05, >10 rats were needed for each group. 
Statistical comparisons among the groups were performed using the 1-way Kruskal- 
Wallis test. Paired comparisons between treatment and control groups were performed 
using the Mann-Whitney U test. P < 0.05 was considered statistically significant. Statis- 
tical analyses were performed using the software Statistics for Windows (Release 4.2; 
version 6, StatSoft, Inc., Tulsa, Oklahoma). 
RESULTS 
A total of 50 rats (10 per group) were used in the study. Their mean (SD) age was 10 (3) weeks, 
and mean (SD) weight was 295 (10) g. There was no indication of abnormal behavior, 
decreased food consumption, orabnormal weight gain observed uring the study. 
Observational assessments found that all groups had similar patterns of sexual 
orientation towards females, based on the number of anal-genital exploratory behavior 
episodes before the first mount. 
Table I summarizes the effects of single doses of D-004 and LESP on the sexual 
activity behavior of male rats when exposed to sexually receptive female rats. There 
were no significant differences observed in the mean number of mounts, mount latency, 
the number of intromissions, or intromission latency in the groups treated with D-004 
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Table I. Effects of a single dose of D-O04 (a lipid extract of the fruit of the Cuban royal 
palm [Roystonea regia]) or the lipidosterolic extract of saw palmetto (LESP) on 
the sexual activity in male rats (N = 50). Data are mean (SEM).* 
Mounts, Mount Intromissions, Intromission 
Group No. Latency, sec No. Latency, sec 
D-O04 
400 mg/kg 42 (7.0) 64 (6.0) 19 (3.9) 238 (21.4) 
800 mg/kg 40 (6.4) 65 (8.1) 19 (3.2) 231 (17.9) 
LESP 
400 mg/kg 42 (6.1) 62 (6.1) 20 (2.8) 234 (17.4) 
800 mg/kg 39 (7.3) 61 (6.0) 18 (3.4) 235 (30.6) 
Control 41 (6.7) 63 (5.6) 20 (3.2) 237 (24.2) 
*There were no significant between-group differences. 
or LESP with doses of 400 and 800 mg/kg compared with the control group. There 
were also no between-group differences in sexual activity behavior among the active 
treatment groups. 
Table II illustrates the treatment effects of D-004 and LESP after being adminis- 
tered for 30 days. There were no significant differences observed in the mean number 
of mounts, mount latency, the number of intromissions, or intromission latency in the 
groups treated with D-004 or LESP with either 400 or 800 mg/kg compared with the 
control group. There were also no between-group differences in sexual activity behavior 
among the active treatment groups. 
Table II. Effects of 30  days of t reatment with D-O04 (a lipid extract of the fruit of 
the Cuban royal palm [Roystonea regia]) or the lipidosterolic extract of saw 
palmetto (LESP) on the sexual activity in male rats (N = 50).  Data are mean 
(SEM).* 
Mounts, Mount Intromissions, Intromission 
Group No. Latency, sec No. Latency, sec 
D-O04 
400 mg/kg 45 (8,6) 52 (4,2) 24 (4,4) 222 (20,9) 
800 mg/kg 44 (5.9) 54 (4.0) 25 (3.7) 210 (18.1) 
LESP 
400 mg/kg 46 (8.4) 50 (4.9) 22 (5.3) 211 (15.2) 
800 mg/kg 48 (9.9) 51 (5.7) 26 (5.6) 215 (14.9) 
Control 47 (8.8) 53 (5.6) 27 (4.6) 217 (19.4) 
*There were no significant between-group differences. 
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DISCUSSION 
Our findings suggest that LESP does not affect male sexual activity in rats. The number of 
mounts and intromissions and the latency of both did not change when LESP was admin- 
istered orally once or repeatedly (400 and 800 mg/kg) for 30 days. Similar results were 
obtained with D-004, despite its ability to competitively and dose-dependently inhibit the 
activity of prostate 50~-reductase in vitro 29 and to prevent PH induced with testosterone in 
rodents when it has been administered atdoses from 200 to 800 mg/kg. 3° 33 
Because of the role androgens play in male sexual function, inhibiting prostate 
5o~-reductase activity might affect sexual activity. Clinical studies 13,42,43 have found 
that finasteride was associated with an increase in AEs affecting male sexual function 
(ie, decreased libido, ejaculatory disorders, and impotence). 
LESP has been found to inhibit 5o~-reductase, 21 26 although no such effect was found 
in 1 study. 44 LESP inhibits moderately and competitively (up to 50%) the binding of 
DHT to cystosolic prostate receptors in rats, cultured human foreskin fibroblasts, 45
and the uptake of DHT in other human tissues by 41% to 42%, 46 although an isolated 
study found no effect on DHT uptake results. 44 The antiandrogenic effects of LESP 
suggest hat it might affect male sexual activity. Studies 13,17,28 have found that the rate 
of AEs associated with LESP administration related to male sexual activity is similar to 
that with placebo and less than with finasteride. A lack of effect on male sexual activity 
in animals was referred to in a product monograph. 47
Despite clinical studies 13,42,43 that have found that finasteride might affect male 
sexual function, referenced experimental studies 47,48 have found that rat sexual activi- 
ty was not affected, although fertility was decreased. In a study 48 in gestational rats, 
finasteride (20 mg/kg) had long-term effects on sexual activity in mature rats (aged 
>15 weeks, as per this study's criteria). The male rats were able to mate with untreated 
females, but fertility was decreased, probably due to abnormally shaped sperm, since the 
sperm count remained unchanged. The treatment increased plasma testosterone concen- 
tration, while leaving luteinizing hormone concentration unchanged. An experimental 
study 49 published in 1991 found that finasteride administered ata higher dose (80 mg/kg) 
to sexually mature male rats for 24 to 38 weeks was associated with a 30% to 40% 
decrease in fertility without affecting sexual indices, such as sexual activity behavior 
(eg, mounts, intromissions) or function (ie, ejaculation). This effect was considered to 
be species-specific due to the inability to form copulatory plugs, which are necessary in 
rats but not in other species. 
It is appropriate to use the copulatory activity of normal adult male rats to assess 
the effects of treatments that might affect such activity. 34 37 The copulatory behavior 
of mature male rats is characterized by serially alternating mounts and intromissions 
culminating in ejaculations that show a reproducible pattern in each animal. Because 
inexperienced rats require time to achieve a stable copulatory pattern, it is important 
to include rats that demonstrate brisk sexual activity. 34,4° 
Considering the close relationship between R regia and S repens palms (Arecaceae), 
the similarities in the fatty acid composition of D-004 and LESP (both rich in oleic, 
lauric, and myristic acids) as well as their pharmacologic effects, and the lack of deleteri- 
ous effects of both agents on male rat sexual activity, seem to be consistent. 
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L IM ITAT IONS 
This study alone cannot be used to determine whether these agents have no effect 
on male rat sexual activity. The existing evidence presented by the lack of effect on 
rat male sexual behavior might be sufficient for LESR because no differences in male 
sexual function with regard to placebo have been found in clinical studies. 12,16 D-004, 
however, is a newer substance that requires further study with longer treatment periods 
and higher doses to ensure its lack of effect on sexual activity. In addition, further stud- 
ies using positive control groups treated with compounds that negatively affect male 
rat copulatory behavior (eg, sodium nitroprusside, various antihypertensive drugs) are 
needed. 
CONCLUSION 
D-004 and LESP administered as a single dose or repeated oses (400 and 800 mg/kg) 
for 30 days did not significantly affect male rat sexual activity behavior compared with 
control. 
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